New Mild and Simple Approach to Isothiocyanates: A Class of Potent Anticancer Agents.

Bingling Luo,Jiankang Wang,Jing Yang,Peng Huang,Yumin Hu,Xiaobing Li,Shijun Wen,Wenhua Lu

doi:10.3390/molecules22060773

Abstract

In our current work, acetyl chloride-mediated synthesis of phenethyl isothiocyanate (PEITC) derivatives proves to be convenient and provides the expected products at good to excellent yields. Biological evaluation and structure-activity relationship analysis found that the novel compound 7 showed the best anticancer activity against human cancer cell line Panc1 and HGC27 compared with PEITC. Compounds 6 and 7 induced more apoptosis in pancreatic cancer cells but less toxicity in non-cancer cells. Further biological study demonstrated that 7 substantially increased intracellular reactive oxygen species (ROS) and depleted glutathione (GSH), leading to an oxidative stress to kill cancer cell.

Highlights

Isothiocyanates are important natural compounds found in cruciferous vegetables such as watercress and broccoli, and they have shown cancer prevention effects [1,2]
In isothiocyanates, a slight excess of tosyl encounter in the thesynthesis synthesisofofless lesspolar polar isothiocyanates, a slight excess of chloride was was always difficult to remove from the products by flash
This hampered our progress in obtaining a variety of compounds, it is it ofishigh interest to find problem hampered our progress in obtaining a variety of compounds, of high interest to an alternative concise method of doing so

Summary

Introduction

Isothiocyanates are important natural compounds found in cruciferous vegetables such as watercress and broccoli, and they have shown cancer prevention effects [1,2]. It is reported that these natural isothiocyanates can induce apoptosis of cancer cells, its mechanism is still under debate [3,4,5,6]. Among these reported natural compounds, one of the most studied is phenethyl isothiocyanate (PEITC). PEITC has been registered for clinical trials for cancer prevention and treatment (ClinicalTrials.gov Identifiers: NCT00005883, NCT00691132, NCT01790204)

Methods

Discussion

Conclusion